Biogenvs.Vertex Pharmaceuticals
BIIB vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 3.9× larger than Biogen by market cap; Vertex Pharmaceuticals trades at the lower P/E (29.0 vs 39.4); year to date, Biogen leads (+24.1% vs +11.0%).
Side by side
| BIIB | VRTX | |
|---|---|---|
| Market cap | $32.9B | $128B |
| Price | $225.71 | $510.08 |
| Today | +3.3% | +1.4% |
| Return YTD | +24.1% | +11.0% |
| Return 1Y | +44.7% | +19.5% |
| Since June 26, 2026 | +4.5% | +3.8% |
| P/E | 39.4 | 29.0 |
| P/S | 3.3 | 10.1 |
| P/B | 1.7 | 6.3 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More BIIB & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.